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AbstrAct
This study compared a novel low-cost solar 
powered direct ophthalmoscope called the 
Arclight with a traditional direct ophthalmoscope 
(TDO). After appropriate training, 25 Malawian 
eye healthcare workers were asked to examine 
12 retinal images placed in a teaching manikin 
head with both the Arclight ophthalmoscope 
and a traditional direct ophthalmoscope (Keeler 
Professional V.2.8). Participants were scored on 
their ability to identify clinical signs, to make a 
diagnosis and how long they took to make a 
diagnosis. They were also asked to score each 
ophthalmoscope for ‘ease of use’. Statistically 
significant differences were found in favour 
of the Arclight in the number of clinical signs 
identified, correct diagnoses made and ease of 
use. The ophthalmoscopes were equally effective 
as a screening tool for diabetic retinopathy, and 
there was no statistically difference in time to 
diagnosis. The authors conclude that the Arclight 
offers an easy to use, low cost alternative to the 
traditional direct ophthalmoscope to meet the 
demands for screening and diagnosis of visually 
impairing eye disorders in low-income and 
middle-income countries.
IntroductIon
Over 285 million people worldwide suffer 
from significant visual impairment of 
which approximately 60%–70% is consid-
ered to be preventable and treatable.1 2 The 
majority of cases reside in low-income and 
middle-income countries (LMICs)1 where 
access to diagnostic tools is least.3 4 Early 
identification and treatment, particularly 
of those conditions affecting the retina 
and optic nerve, relies on tools such as the 
traditional direct ophthalmoscope (TDO).
Although the TDO has traditionally 
been one of the main ophthalmic screening 
and diagnostic tools, it has limitations 
of high initial cost of purchase, require-
ment for regular maintenance (bulbs 
and batteries) and perceived difficulty 
of use.5 6 Consequently, the ‘functional’ 
availability of this important device in 
LMICs is limited.
The Vision 2020 Right to Sight initia-
tive is a global strategy, launched in 
1999, with the aim to eliminate avoid-
able blindness by 2020.7 The initiative 
has three main aims: disease control, 
human resource development and infra-
structure strengthening including rele-
vant technology development for eye care 
delivery.8 Along with the Lancet Commis-
sion,9 recommendations have emphasised 
the development of ‘frugal’ and cultur-
ally appropriate technology for users in 
LMICs.
In response to these challenges, a novel 
low-cost multipurpose diagnostic device 
has been developed by Arclight Medical10 
employing a number of innovative and 
unique design features (figure 1).
The key patented feature of the device is 
to employ a Light Emitting Diode (LED), 
which can be charged by an integrated 
photovoltaic (solar) panel. This novel 
design eliminates the need for bulky, hard 
to source and expensive replacement fila-
ment bulbs and batteries and mains elec-
tricity charging. The LED is small enough 
to be placed directly below the viewing 
hole, facing the patient, creating a near 
axial light source (figure 2), avoiding using 
a mirror to redirect light from below as is 
traditionally done. These design changes 
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create a slim (110 mm long×26 mm wide×9 mm thick) 
and light device (18 g).
Additionally, the Arclight has an integrated magni-
fying loupe and otoscope broadening its diagnostic 
potential. As it is available at only £5.00 to low-in-
come users when sold in bulk,11 it is potentially an 
economically and practical alternative to TDOs in 
LMICs. As yet, however, no studies have evaluated 
the effectiveness of the Arclight in diagnosing retinal 
disorders (including diabetic retinopathy) among eye 
care providers in a LMIC.
the aim of this study
The aim of the study is to compare how the Arclight 
device performs in comparison to a TDO when used 
by Malawian eye healthcare professionals examining 
the fundi of simulated eyes.
MAterIAls And Methods
Appropriate ethical approval was obtained. Twen-
ty-five eye healthcare professionals and optometry 
students were recruited with fully informed consent. 
Participants were recruited from two hospital eye 
departments and one school of optometry.
The participants were already familiar with using a 
TDO. An introductory ‘refresher’ session was provided 
on direct ophthalmoscopy and the examiners had a 
brief training session with the Arclight to familiarise 
themselves with the practicalities of how the device 
works.
Figure 1 The Arclight with selected features highlighted.
Figure 2 The Arclight illumination uses a light emitting diode placed directly below the viewing hole, facing the patient, creating a 
near-axial light source unlike the traditional direct ophthalmoscope, which uses a mirror to redirect light into an axial path.
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clinical signs, diagnosis and ease of use (eou) scores
Participants were asked to examine 12 retinal pathology 
slides placed in an Adam-Rouilly teaching manikin 
head (figure 3). Slides included background retinop-
athy and diabetic maculopathy, preproliferative reti-
nopathy, advanced proliferative retinopathy, diabetic 
maculopathy, pan laser photocoagulation, normal 
fundus, glaucomatous disc, papilloedema/swollen disc, 
toxoplasmosis scar/optic atrophy, cytomegalovirus, 
central retinal vein occlusion and central retinal artery 
occlusion. A cross-over design was utilised with 12 
participants using the Arclight first (group 1) and the 
TDO second and 13 participants the converse (group 
2). The TDO used in this study was a Keeler Profes-
sional V.2.8. The order of the slides was randomised 
before ‘crossing over’.
The participants were asked to describe the clinical 
signs they saw on the slide and to provide a diagnosis. 
Every clinical sign correctly identified received one 
mark. The time taken to reach a diagnosis was also 
recorded. Correct diagnoses, recognition of clin-
ical signs and time taken to diagnose were normally 
distributed and a paired t-test was used to assess statis-
tical significance.
Participants were additionally asked to rate the EOU 
as described below:
1. Could not use this ophthalmoscope to see the red reflex.
2. Could see the red reflex.
3. Could not focus the fundus.
4. Could see vessels but not optic disc.
5. Could see the disc and retinal fields but it was not in 
focus.
6. Could see the disc and retinal fields in focus with high 
level of difficulty.
7. Could see disc and retinal fields in focus with medium 
level of difficulty.
8. Could see disc and retinal fields in focus with low level 
of difficulty.
For descriptive statistics, an EOU score greater than 7 
was defined as ‘easy’ and less than 6 (</6) as ‘difficult’. 
The EOU score frequency was not normally distrib-
uted and a non-parametric Wilcoxon sign rank test was 
applied.
results
Identification of clinical signs
A possible 53 pathological features could be diagnosed 
in the 12 slides. Arclight mean score per participant 
was 31.6 (95% CI 28.85 to 34.35) and TDO 28.72 
(95% CI 26.42 to 31.01). Participants using the 
Arclight were significantly better at correctly identi-
fying clinical signs compared with the TDO; the mean 
difference in the total number of correctly identified 
features by each participant was 2.89 in favour of the 
Arclight, t=3.285, P=0.003, 95% CI 1.13 to 4.65.
Pathology diagnosis
Fourteen possible diagnoses could be made from 
the 12 slides; Arclight mean score was 9.8 (95% CI 
8.87 to 10.73) and the TDO 9.12 (95% CI 8.23 to 
10.01). Users of the Arclight were significantly better 
at correctly diagnosing the pathology illustrated on 
the slide; the mean difference in the number of slides 
correctly diagnosed by participants was 0.685 in 
favour of the Arclight, t=2.957, P=0.007, 95% CI 
0.21 to 1.17 .
Four of the 12 slides displayed solely signs of 
diabetic retinopathy (DR), so a maximum of 100 DR 
slides could be identified by all 25 participants, using 
the Arclight; participants correctly identified 83 slides 
with DR signs and the TDO 79 slides. When analysing 
Figure 3 The Arclight being used with teaching slides in a manikin head.
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theses signs, the sensitivity of the Arclight was 83% 
(95% CI 75.63 to 90.36) and TDO 79% (95% CI 
71.01 to 87.00) and specificity of the Arclight was 
98% (95% CI 96.06 to 99.94) and TDO 97.5% (95% 
CI 95.34 to 99.66) demonstrating that the devices 
were comparable to each other as a screening tool.
time to diagnosis
Arclight mean time per slide was 93.19 s (95% CI 
80.40 to 105.98) and TDO mean 103.15 s (95% CI 
85.99 to 120.31). There was a non-significant trend 
for participants to make faster diagnoses with the 
Arclight; the mean difference between the time taken 
by participants to diagnose each slide was −8.95 s in 
favour of the Arclight, t=1.978, with P=0.06, 95% CI 
−18 to 0.1.
eou score
For every examination, the user recorded a subjective 
EOU score; overall 300 examinations were performed 
with each device. More examinations were rated as 
‘easy’ (defined as a score greater than 7) when using 
the Arclight (68%) compared with the TDO (59%). 
Mean score for Arclight was 6.7 (SEM±0.16) and 
TDO 6.5 (SEM±0.16). Using the Wilcoxon Sign rank 
test, this was statistically significant (P=0.01).
dIscussIon
Health clinics in LMICs often become ‘grave yards’ of 
redundant non-functional devices.9 Diagnostic tools 
are usually designed for health systems of wealthy 
countries, leading to expensive and overly complex 
devices, which are unnecessarily challenging to use and 
hard to maintain.3
This study has shown that the Arclight can satisfy 
the recommendations of the Vision 202012 initiative 
and the Lancet Commission9 to develop devices for 
LMICs that are low cost, portable and independent of 
scarce and expensive consumables while not compro-
mising the core function. In the hands of Malawian 
eye care workers, the Arclight, despite being many 
fold less expensive than TDOs, performed better. This 
supports Lowe et al’s5 previous study demonstrating 
the Arclight to be a suitable alternative to the TDO 
for the purpose of screening and accurately diagnosing 
optic nerve disease.
Our study is also consistent with this previous study 
demonstrating the Arclight to be easier to use than a 
TDO. Possible reasons for this include the simplified 
design of the Arclight with a minimum of switches and 
dials creating an intuitive and uncomplicated device. 
Also, as previously mentioned, the Arclight is small, 
light and importantly very slim (9 mm thick) allowing 
the user to get closer to the pupil plane of the patient 
potentially offering a wider more stable field of view 
(figure 2). These features may also help to explain why 
users are more accurate at identifying retinal signs and 
make more correct diagnoses compared with when 
using a TDO.
There were, however, important limitations to this 
study. An Adam Rouilly teaching head with simulated 
eyes cannot replicate media opacity, variability in pupil 
size or the head and eye movement of a real patient 
and consequently further comparative studies using 
real patients and in particular those with diabetic reti-
nopathy should be considered in the future.5 13
An additional limitation is that participant’s previous 
training, experience and familiarity with a TDO may 
have negatively influenced their impression of the 
Arclight.6 Despite this, the Arclight was considered 
easier to use than the TDO in this study emphasising 
the simplified and intuitive design as a major strength 
of the device.
Further studies should explore the other functions 
of the device, including the anterior segment loupe, 
which allows differentiation of causes of medial opacity 
(eg, cataract vs corneal scar) and a magnified view of 
the tarsal plates for diagnosis and grading trachoma.14 
Additionally, no studies have evaluated the effective-
ness of the otoscope function.
conclusIon
In conclusion, this study provides additional evidence 
that the Arclight is a genuine practical and economic 
alternative to the TDO. By overcoming barriers to 
acquisition, maintenance and practical use that are 
present in low-resource settings, the device represents 
an important addition to the current strategies being 
employed to reduce the global burden of blindness.2 In 
addition, the Arclight can also function as a loupe and 
otoscope and consequently could have a broader role 
to play in healthcare.
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